| Literature DB >> 35126862 |
Masashi Takeuchi1, Hirofumi Kawakubo2, Satoru Matsuda1, Shuhei Mayanagi1, Tomoyuki Irino1, Jun Okui3, Kazumasa Fukuda1, Rieko Nakamura1, Norihito Wada1, Hiroya Takeuchi4, Yuko Kitagawa1.
Abstract
BACKGROUND: Despite improvements in surgical procedures and peri-operative patients management, the postoperative complications in esophagogastric junction (EGJ) cancer remain high because of technical aspects. Several studies have indicated the negative influence of postoperative infectious complications on long-term survival after gastrointestinal surgery. However, no study has shown the association between postoperative complications and long-term survival of patients with EGJ cancer. AIM: To elucidate influence of postoperative complications on the long-term outcomes of patients with EGJ cancer.Entities:
Keywords: Complication; Esophagogastric junction cancer; Long-term outcome
Year: 2022 PMID: 35126862 PMCID: PMC8790330 DOI: 10.4240/wjgs.v14.i1.46
Source DB: PubMed Journal: World J Gastrointest Surg
Clinicopathologic characteristics of the study population
|
|
|
| Sex | |
| Male/female | 96 (78.7%)/26 (21.3%) |
| Age, median (min, max) | 68 (35-87) |
| Histology | |
| Adenocarcinoma/squamous cell carcinoma | 95 (77.9%)/27 (22.1%) |
| Neoadjuvant | 32 (26.2%) |
| Adjuvant | 27 (22.1%) |
| Approach | |
| Transthoracic/transhiatal | 47 (38.5%)/75 (61.5%) |
| Reconstruction site | |
| Cervical/Intrathoracic | 22 (18.0%)/100 (82.0%) |
| Subtotal esophagectomy | 41 (33.6%) |
| Total gastrectomy | 37 (30.3%) |
| Splenectomy | 16 (13.1%) |
| Operating time (min); median (range) | 299 (114-775) |
| Amount of bleeding (mL); median (range) | 180 (10-4858) |
| Tumor epicenter | |
| Esophageal side/gastric side | 52 (42.6%)/70 (57.4%) |
| Distance from the EGJ to the tumor center (mm) | 1.5 (-20 |
| Esophageal invasion (mm) | 11.5 (0-55) |
| Tumor diameter (mm) | 32 (6-100) |
| Pathologic stage of esophageal cancer | |
| Stage I/stage II/stage III/stage IV | 44 (36.1%)/24 (19.7%)/38 (31.2%)/16 (13.1%) |
| Residual cancer | |
| R0/R1 | 111 (91.0%)/11 (9.0%) |
This indicates that tumor epicenter is located on gastric side. EGJ: Esophagogastric junction.
Postoperative complications
|
|
|
|
| Overall complications | 40 (32.8%) | 17 (13.9%) |
| Pneumonia | 12 (9.8%) | 1 (0.8%) |
| Anastomotic leakage | 8 (6.6%) | 7 (5.7%) |
| Recurrent laryngeal nerve paralysis | 6 (5%) | 0 |
| Wound infection | 4 (3.3%) | 0 |
| Chyle leakage | 3 (2.5%) | 2 (1.7%) |
| Hemorrhage | 2 (1.7%) | 2 (1.7%) |
| Pancreatic fistula | 3 (2.5%) | 0 |
| Atrial fibrillation | 2 (1.7%) | 0 |
| Abdominal abscess | 3 (2.5%) | 1 (0.8%) |
| Gastric tube-bronchial fistula | 1 (0.8%) | 1 (0.8%) |
| Others | 9 (7.4%) | 3 (2.5%) |
Figure 1Kaplan-Meier survival curves, according to the presence of pneumonia. A: Overall survival; B: Recurrence-free survival. Red and blue lines indicate the groups with and without pneumonia, respectively.
Figure 2Kaplan–Meier survival curves, according to the presence of anastomotic leakage. A: Overall survival; B: Recurrence-free survival. Red and blue lines indicate the groups with and without anastomotic leakage, respectively.
Predictors for overall survival on univariate and multivariate analyses
|
|
|
| ||
|
|
|
|
| |
| Male ( | 0.71 (0.34–1.49) | 0.365 | ||
| Age (per 1 year increase) | 1.06 (1.02-1.09) | 0.004 | 1.05 (1.01-1.08) | 0.014 |
| SCC ( | 2.06 (1.02-4.16) | 0.045 | 1.20 (0.50-2.87) | 0.674 |
| Neoadjuvant + ( | 2.22 (1.11-4.44) | 0.025 | 1.61 (0.72-3.58) | 0.244 |
| Adjuvant + ( | 1.76 (0.86-3.62) | 0.122 | ||
| Transthoracic approach ( | 1.64 (0.83-3.22) | 0.148 | ||
| pStage III/IV ( | 9.55 (3.68-24.76) | < 0.001 | 7.14 (2.67-19.13) | < 0.001 |
| R1 ( | 2.62 (1.08-6.35) | 0.033 | 1.79 (0.69-4.68) | 0.232 |
| Anastomotic leakage | 3.07 (1.07-8.80) | 0.037 | 3.59 (1.11-11.58) | 0.032 |
| Postoperative pneumonia | 1.68 (0.59-4.78) | 0.332 | ||
P: Pathologic; SCC: Squamous cell carcinoma; AC: Adenocarcinoma; R0: No residual tumor; R1: Microscopic residual tumor; HR: Hazard ratio.
Figure 3Kaplan–Meier survival curves, according to the presence of anastomotic leakage and type of anastomosis. A and B: The overall survival (A) in patients with cervical anastomosis and (B) in patients with intrathoracic anastomosis; C and D: The recurrence-free survival (C) in patients with cervical anastomosis and (D) in patients with intrathoracic anastomosis. Red and blue lines indicate the groups with and without anastomotic leakage, respectively.
Patterns of recurrence
|
|
|
| ||
|
|
| |||
| Hematogenous | 19 (15.6%) | 4 (50%) | 15 (13.2%) | 0.005 |
| Lymphatic | 23 (18.9%) | 3 (37.5%) | 20 (17.5%) | 0.163 |
| Peritoneal | 7 (5.7%) | 2 (25%) | 5 (4.4%) | 0.015 |
| Local | 4 (3.3%) | 2 (25%) | 2 (1.8%) | < 0.001 |